Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment

BJU International

Volumn 109, Issue 2, 2012, Pages 200-206

  Mancuso, Andrea ^a   Di Paola, Eugenio Donato ^a   Leone, Alvaro ^a   Catalano, Alfonso ^b   Calabrò, Fabio ^a   Cerbone, Linda ^a   Zivi, Andrea ^a   Messina, Carlo ^a   Alonso, Silvia ^a   Vigna, Leonardo ^a   Caristo, Rita ^a   Sternberg, Cora N ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

prognostic and predictive markers; renal cell carcinoma; second line treatment

Indexed keywords

B RAF KINASE; BEVACIZUMAB; PAZOPANIB; SORAFENIB; SUNITINIB; VASCULOTROPIN A;

ADULT; AGED; ANEMIA; ARTICLE; B RAF GENE; CANCER CONTROL; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; FATIGUE; FEMALE; FOLLOW UP; GENE MUTATION; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; METASTASIS; MOLECULAR PATHOLOGY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; ONCOGENE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RASH; SALVAGE THERAPY; TRANSLATIONAL RESEARCH; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; BENZENESULFONATES; CARCINOMA, RENAL CELL; DIARRHEA; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HAND-FOOT SYNDROME; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUCOSITIS; NEOPLASM METASTASIS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84555208775     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10421.x     Document Type: Article

References (29)

1. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C,. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008; 34: 193-205
2. Escudier B, Eisen T, Stadler WM, et al,. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-8
3. Motzer RJ, Hutson TE, Tomczak P, et al,. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24 (Pubitemid 46089672)
4. Sternberg CN, Davis ID, Mardiak J, et al,. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8
5. Escudier B, Kataja V, ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4): 81-2
6. Rini BI, Halabi S, Rosenberg JE, et al,. Phase III trial of bevacizumab plus interferon alpha versus interferon alpha monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-43
7. Escudier B, Kataja V,. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v137-9
8. Dudek AZ, Zolnierek J, Dham A, et al,. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115: 61-7
9. Di Lorenzo G, Cartenì G, Autorino R, et al,. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009; 27: 4469-74
10. Garcia JA, Hutson TE, Elson P, et al,. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 2010; 116: 5383-90
11. National Cancer Institute. Common terminology criteria for adverse events v3.0. Available at
12. Heinrich MC, Corless CL, Duensing A, et al,. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-10 (Pubitemid 36159485)
13. Corless CL, McGreevey L, Haley A, et al,. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160: 1567-72 (Pubitemid 34525636)
14. Rader AE, Avery A, Wait CL, et al,. Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit. Cancer 2001; 93: 269-75 (Pubitemid 32777534)
15. Choy YS, Dabora SL, Hall F, et al,. Superiority of denaturing high performance liquid chromatography over single-stranded conformation and conformation-sensitive gel electrophoresis for mutation detection in TSC2. Ann Hum Genet 1999; 63: 383-91 (Pubitemid 30128886)
16. Heinrich MC, Corless CL, Blanke CD, et al,. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 4764-74 (Pubitemid 46630941)
17. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 52: 457-81
18. Motzer RJ, Bacik J, Murphy BA, et al,. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-96 (Pubitemid 34032623)
19. Mendel DB, Lard AD, Xin X, et al,. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37 (Pubitemid 36109749)
20. Wilhelm SM, Carter C, Tang L, et al,. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109 (Pubitemid 39331023)
21. Mizukami Y, Kohgo Y, Chung DC,. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 2007; 13: 5670-4 (Pubitemid 47583891)
22. Rini BI, Atkins MB,. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992-1000
23. Caraglia M, Tassone P, Marra M, Budillon A, Venuta S, Tagliaferri P,. Targeting Raf-kinase: molecular rationales and translational issues. Ann Oncol 2006; 17 (Suppl. 7): 124-7
24. Motzer RJ, Escudier B, Oudard S, et al,. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56
25. Tamaskar I, Garcia JA, Elson P, et al,. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008; 179: 81-6 (Pubitemid 350216728)
26. Rixe O, Bukowski RM, Michaelson MD, et al,. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007; 8: 975-84 (Pubitemid 47629888)
27. Rini BI, Michaelson MD, Rosenberg JE, et al,. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-8
28. Motzer RJ, Escudier B, Oudard S, et al,. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-65
29. National Institutes of Health. Protocols (NCT00126503). Available at:. Accessed 2 November 2011